Krishnan Nandabalan
Over the past ten years, Krishnan Nandabalan, Ph.D. President and CEO, InveniAI Corp and Co-Founder of Parent Company,... | Branford, Connecticut, United States
*50 free lookup(s) per month.
No credit card required.
Krishnan Nandabalan’s Emails kn****@bi****.com
Krishnan Nandabalan’s Phone Numbers No phone number available.
Social Media
Krishnan Nandabalan’s Location Branford, Connecticut, United States
Krishnan Nandabalan’s Expertise Over the past ten years, Krishnan Nandabalan, Ph.D. President and CEO, InveniAI Corp and Co-Founder of Parent Company, BioXcel Corporation has pioneered the development of big data analytics, AI and ML and its application in monitoring emerging innovation through the assimilation and query of large data sets. This resulted in the successful spinout of the biotech company BioXcel Therapeutics (NASDAQ: BTAI) as well as the technology spinout InveniAI Corporation, where he is now the President and CEO. Dr. Nandabalan has over two decades of experience in the pharmaceutical and biotechnology industries, including R&D, operations, and business development. He has extensive experience in M&A and in/out-licensing and has completed deals with key industry players such as Pfizer, J&J, AstraZeneca, Pharmacia, BMS, Biogen, Millennium Pharmaceuticals, Merck KGaA, Organon, Daiichi Sankyo, and Otsuka, Takeda, Kyowa Hakko Kirin among others. He served as VP, Corporate Development at Genaissance Pharmaceuticals, a trailblazer in the widespread acceptance of pharmacogenomics. Prior to this, he was Group Leader of the Functional Genomics Group at CuraGen Corp. He has 12 issued patents and published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India and was a Post-Doctoral Fellow at Yale University. Dr. Nandabalan has a thorough understanding of the applications of artificial intelligence to drive innovation.
Krishnan Nandabalan’s Current Industry Invea Therapeutics
Krishnan
Nandabalan’s Prior Industry
Curagen
|
Genaissance Pharmaceuticals
|
Bioxcel
|
Inveniai
|
Bioxcel Therapeutics
|
Invea Therapeutics
Not the Krishnan Nandabalan you were looking for?
Find accurate emails & phone numbers for over 700M professionals.
Work Experience
Invea Therapeutics
Founder, Chairman, President, CEO
Mon Nov 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) — Present
Inveniai
Board Member
Sat Apr 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) — Present
Inveniai
President, CEO, and Founder
Sat Apr 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) — Present
Bioxcel Therapeutics
Board Member
Sat Apr 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Sep 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Bioxcel
President and Co-Founder
Thu Sep 01 2005 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Sep 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Bioxcel
Board Member
Thu Sep 01 2005 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri Sep 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Genaissance Pharmaceuticals
VP Corporate Development
Thu Jan 01 1998 00:00:00 GMT+0000 (Coordinated Universal Time) — Sat Jan 01 2005 00:00:00 GMT+0000 (Coordinated Universal Time)
Curagen
Group Leader, Functional Genomics
Sun Jan 01 1995 00:00:00 GMT+0000 (Coordinated Universal Time) — Tue Sep 01 1998 00:00:00 GMT+0000 (Coordinated Universal Time)Skills
Languages
Krishnan Nandabalan Email Addresses
FAQ About Krishnan Nandabalan
-
Krishnan Nandabalan is located at
Branford, Connecticut, United States -
Krishnan Nandabalan is a
Over the past ten years, Krishnan Nandabalan, Ph.D. President and CEO, InveniAI Corp and Co-Founder of Parent Company, BioXcel Corporation has pioneered the development of big data analytics, AI and ML and its application in monitoring emerging innovation through the assimilation and query of large data sets. This resulted in the successful spinout of the biotech company BioXcel Therapeutics (NASDAQ: BTAI) as well as the technology spinout InveniAI Corporation, where he is now the President and CEO. Dr. Nandabalan has over two decades of experience in the pharmaceutical and biotechnology industries, including R&D, operations, and business development. He has extensive experience in M&A and in/out-licensing and has completed deals with key industry players such as Pfizer, J&J, AstraZeneca, Pharmacia, BMS, Biogen, Millennium Pharmaceuticals, Merck KGaA, Organon, Daiichi Sankyo, and Otsuka, Takeda, Kyowa Hakko Kirin among others. He served as VP, Corporate Development at Genaissance Pharmaceuticals, a trailblazer in the widespread acceptance of pharmacogenomics. Prior to this, he was Group Leader of the Functional Genomics Group at CuraGen Corp. He has 12 issued patents and published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India and was a Post-Doctoral Fellow at Yale University. Dr. Nandabalan has a thorough understanding of the applications of artificial intelligence to drive innovation. Invea Therapeutics -
Krishnan Nandabalan currently works in the
Invea Therapeutics -
Krishnan Nandabalan specializes in
Over the past ten years, Krishnan Nandabalan, Ph.D. President and CEO, InveniAI Corp and Co-Founder of Parent Company, BioXcel Corporation has pioneered the development of big data analytics, AI and ML and its application in monitoring emerging innovation through the assimilation and query of large data sets. This resulted in the successful spinout of the biotech company BioXcel Therapeutics (NASDAQ: BTAI) as well as the technology spinout InveniAI Corporation, where he is now the President and CEO. Dr. Nandabalan has over two decades of experience in the pharmaceutical and biotechnology industries, including R&D, operations, and business development. He has extensive experience in M&A and in/out-licensing and has completed deals with key industry players such as Pfizer, J&J, AstraZeneca, Pharmacia, BMS, Biogen, Millennium Pharmaceuticals, Merck KGaA, Organon, Daiichi Sankyo, and Otsuka, Takeda, Kyowa Hakko Kirin among others. He served as VP, Corporate Development at Genaissance Pharmaceuticals, a trailblazer in the widespread acceptance of pharmacogenomics. Prior to this, he was Group Leader of the Functional Genomics Group at CuraGen Corp. He has 12 issued patents and published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India and was a Post-Doctoral Fellow at Yale University. Dr. Nandabalan has a thorough understanding of the applications of artificial intelligence to drive innovation. -
Krishnan Nandabalan speaks the following languages:
No languages available. -
Krishnan Nandabalan has prior experience in the following industries:
Bioxcel Therapeutics , Bioxcel , Bioxcel , Genaissance Pharmaceuticals , Curagen -
Krishnan Nandabalan has the following professional experience:
Invea Therapeutics , Inveniai , Inveniai , Bioxcel Therapeutics , Bioxcel , Bioxcel , Genaissance Pharmaceuticals , Curagen . -
You can view Krishnan Nandabalan’s
LinkedIn profile at LinkedIn URL. -
Krishnan Nandabalan’s work email addresses are
[email protected] . -
Krishnan Nandabalan works at
Invea Therapeutics
People you may be interested in
- Mary Minervini
- Daniel Ndimele
- Patrick Marcot
- Prabhat Tripathy
- Jeeva Nandan
- Christina Erlinger
- Mariam Nordstrand
- Washington Ludena
Staffing Recruiter
MA | MBA | Sales | Marketing | Sustainability | Business Development | Marketing Analytics | Business Intelligence | Entrepreneurial Manager
Directeur des établissements chez UTAC
Assistant Manager at Tata Consultancy Services
Sr Field Services Engineer
Programs Manager at Kaplan Test Prep and Admissions
Vårdenhetschef på Region Sörmland, Dagkirurgiska behandlingsavdelningen
Especialista en procesos PET. 940630111 RPC